Literature DB >> 24142717

Impact of probiotics on toll-like receptor 4 expression in an experimental model of ulcerative colitis.

Xia Yang1,2, Yu Fu1, Jun Liu3, Hong-Yu Ren4.   

Abstract

Toll-like receptors (TLRs) are key components of the innate immune system which trigger antimicrobial host defense responses. This study aimed to investigate the impact of probiotics (Lactobacillus, Bifidobacterium) on the expression of TLR4 and tumor necrosis factor-alpha (TNF-α) in the colon mucosa of rat experimental ulcerative colitis model induced by trinitrobenzene sulfonic acid (TNBS)/ethanol and immune complexes. The gross and histological changes of the colonic mucosa were observed and assessed by the means-standard deviation and independent samples t-test. The protein expression levels of TLR4 and TNF-α were detected by using immunohistochemistry and Western blotting, respectively. It was revealed that there was visible infiltration of inflammatory cells, formation of crypt abscess, and the reduction of goblet cells in the colon tissue of experimental models. As compared with the control group, the levels of TLR4 and TNF-α protein were significantly increased in the model group (P<0.01 for both). No significant difference was found in the expression of TLR4 and TNF-α between the two-week probiotics treatment group and the model group (P>0.05), whereas significant reductions were shown in rats which were treated with probiotics for four weeks as compared with the model group (P<0.01). There was no significant difference between two probiotics-treated groups. Our results implied that probiotics were likely to play a key role in protecting ulcerative colitis by reducing the inflammatory factor TNF-α expression through inhibiting the TLR4 expression in the colon tissue of experimental models.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24142717     DOI: 10.1007/s11596-013-1177-9

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  12 in total

Review 1.  Probiotics in the treatment of inflammatory bowel disease.

Authors:  Kevin P Rioux; Richard N Fedorak
Journal:  J Clin Gastroenterol       Date:  2006-03       Impact factor: 3.062

2.  Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis.

Authors:  K Kato; S Mizuno; Y Umesaki; Y Ishii; M Sugitani; A Imaoka; M Otsuka; O Hasunuma; R Kurihara; A Iwasaki; Y Arakawa
Journal:  Aliment Pharmacol Ther       Date:  2004-11-15       Impact factor: 8.171

Review 3.  Microbial influences in inflammatory bowel diseases.

Authors:  R Balfour Sartor
Journal:  Gastroenterology       Date:  2008-02       Impact factor: 22.682

Review 4.  Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis.

Authors:  R Balfour Sartor
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2006-07

5.  Mechanism of regulation of Na-H exchanger in inflammatory bowel disease: role of TLR-4 signaling mechanism.

Authors:  Iqbal Siddique; Islam Khan
Journal:  Dig Dis Sci       Date:  2011-01-08       Impact factor: 3.199

Review 6.  Intestinal dendritic cells in the pathogenesis of inflammatory bowel disease.

Authors:  Sergio Rutella; Franco Locatelli
Journal:  World J Gastroenterol       Date:  2011-09-07       Impact factor: 5.742

7.  Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis.

Authors:  T Kühbacher; S J Ott; U Helwig; T Mimura; F Rizzello; B Kleessen; P Gionchetti; M Blaut; M Campieri; U R Fölsch; M A Kamm; S Schreiber
Journal:  Gut       Date:  2006-01-09       Impact factor: 23.059

8.  Immunostimulatory oligonucleotides inhibit colonic proinflammatory cytokine production in ulcerative colitis.

Authors:  Daniel Rachmilewitz; Fanny Karmeli; Shimon Shteingart; Jongdae Lee; Kenji Takabayashi; Eyal Raz
Journal:  Inflamm Bowel Dis       Date:  2006-05       Impact factor: 5.325

9.  Clinicopathologic study of dextran sulfate sodium experimental murine colitis.

Authors:  H S Cooper; S N Murthy; R S Shah; D J Sedergran
Journal:  Lab Invest       Date:  1993-08       Impact factor: 5.662

10.  Readressing the role of Toll-like receptor-4 alleles in inflammatory bowel disease: colitis, smoking, and seroreactivity.

Authors:  Anastassios C Manolakis; Andreas N Kapsoritakis; Anastasia Kapsoritaki; Elisavet K Tiaka; Konstantinos A Oikonomou; Vassilis Lotis; Dimitra Vamvakopoulou; Ioanna Davidi; Nikolaos Vamvakopoulos; Spyros P Potamianos
Journal:  Dig Dis Sci       Date:  2012-08-24       Impact factor: 3.199

View more
  5 in total

1.  Moxibustion treatment modulates the gut microbiota and immune function in a dextran sulphate sodium-induced colitis rat model.

Authors:  Qin Qi; Ya-Nan Liu; Xiao-Ming Jin; Lin-Shuang Zhang; Cun Wang; Chun-Hui Bao; Hui-Rong Liu; Huan-Gan Wu; Xiao-Mei Wang
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

2.  Animal Models and Pathogenesis of Ulcerative Colitis.

Authors:  Xin Gao; Jia Li; Xueping Pang; Kaiyuan Cong; Chunlei Jiang; Bingxuan Han; Jiawei Gao; Zhihao Wang; Jiangshan Hu; Kaijun Wen; Xinfa Ye; Liwen Dou
Journal:  Comput Math Methods Med       Date:  2022-07-11       Impact factor: 2.809

3.  Preclinical Immunomodulation by the Probiotic Bifidobacterium breve M-16V in Early Life.

Authors:  Maria Del Mar Rigo-Adrover; Àngels Franch; Margarida Castell; Francisco José Pérez-Cano
Journal:  PLoS One       Date:  2016-11-07       Impact factor: 3.240

Review 4.  Evidence of the Anti-Inflammatory Effects of Probiotics and Synbiotics in Intestinal Chronic Diseases.

Authors:  Julio Plaza-Díaz; Francisco Javier Ruiz-Ojeda; Laura Maria Vilchez-Padial; Angel Gil
Journal:  Nutrients       Date:  2017-05-28       Impact factor: 5.717

5.  Effects of probiotics on Toll‑like receptor expression in ulcerative colitis rats induced by 2,4,6‑trinitro‑benzene sulfonic acid.

Authors:  Ping Yao; Fang Tan; Hongliang Gao; Lei Wang; Tao Yang; Yongbo Cheng
Journal:  Mol Med Rep       Date:  2017-02-21       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.